Innovation Pharmaceuticals Inc (IPIX)

[Whoops]

Nice geographical distribution of trial site for Brilacidin-OM which is probably necessary to capture some of the head and neck cancer patients given their is only about 65k diagnosed every year coupled with the exclusion criteria of the study which appears to exclude mouth tumors etc which are generally considered to be head and neck cancers so that is 65K minus a few. I expect enrollment to be slow in this trial. I would think this study would require more trial sites than Prurisol.

In contrast IMO, Prurisol recruitment should be relatively easy and they have so many sites! I would think the Florida sites would have been enough for quick recruitment. I guess Leo wasn't kidding about playing some catch-up with Prurisol.

Both studies run the course of about 11-12 weeks. Prurisol with 100 patients with results expected in April 2016. Brilacidin-OM with 60 patients with results expected in December 2016.

Taking a second look at the inclusion and exclusion criteria for B-OM... it is tight. I suppose its because there is overlapping battle-fields here with infection and cancer. I got the 65k number from Johns Hopkins link below.

http://www.hopkinsmedicine.org/kimmel_cancer_center/centers/head_neck/